- call +1-201-465-4211
- email sales@marketsandresearch.biz
- Call +1-201-465-4211
- Email: sales@marketsandresearch.biz
The Chronic Obstructive Pulmonary Disorder (COPD) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest study, due to COVID-19 pandemic, the global Chronic Obstructive Pulmonary Disorder (COPD) market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospital accounting for % of the Chronic Obstructive Pulmonary Disorder (COPD) global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Short-Acting Bronchodilators segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Chronic Obstructive Pulmonary Disorder (COPD) include GSK, Pfizer, Merck, Novartis, and AstraZeneca, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Chronic Obstructive Pulmonary Disorder (COPD) market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Short-Acting Bronchodilators
Corticosteroids
Methylxanthines
Long-Acting Bronchodilators
Phosphodiesterase-4 Inhibitors
Others
Market segment by Application, can be divided into
Hospital
Clinic
Market segment by players, this report covers
GSK
Pfizer
Merck
Novartis
AstraZeneca
Boehringer Ingelheim
Teva Pharmaceuticals
Ario Pharma
Roche
Ache
Almirall
Aquinox Pharmaceuticals
Asmacure
Astellas Pharma
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Chronic Obstructive Pulmonary Disorder (COPD) product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Chronic Obstructive Pulmonary Disorder (COPD), with revenue, gross margin and global market share of Chronic Obstructive Pulmonary Disorder (COPD) from 2019 to 2022.
Chapter 3, the Chronic Obstructive Pulmonary Disorder (COPD) competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Chronic Obstructive Pulmonary Disorder (COPD) market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Chronic Obstructive Pulmonary Disorder (COPD) research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Product Overview and Scope of Chronic Obstructive Pulmonary Disorder (COPD)
1.2 Classification of Chronic Obstructive Pulmonary Disorder (COPD) by Type
1.2.1 Overview: Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Type in 2021
1.2.3 Short-Acting Bronchodilators
1.2.4 Corticosteroids
1.2.5 Methylxanthines
1.2.6 Long-Acting Bronchodilators
1.2.7 Phosphodiesterase-4 Inhibitors
1.2.8 Others
1.3 Global Chronic Obstructive Pulmonary Disorder (COPD) Market by Application
1.3.1 Overview: Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size & Forecast
1.5 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Forecast by Region
1.5.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Region, (2017-2022)
1.5.3 North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Prospect (2017-2028)
1.5.4 Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Prospect (2017-2028)
1.5.6 South America Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Chronic Obstructive Pulmonary Disorder (COPD) Market Drivers
1.6.2 Chronic Obstructive Pulmonary Disorder (COPD) Market Restraints
1.6.3 Chronic Obstructive Pulmonary Disorder (COPD) Trends Analysis
2 Company Profiles
2.1 GSK
2.1.1 GSK Details
2.1.2 GSK Major Business
2.1.3 GSK Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
2.1.4 GSK Chronic Obstructive Pulmonary Disorder (COPD) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 GSK Recent Developments and Future Plans
2.2 Pfizer
2.2.1 Pfizer Details
2.2.2 Pfizer Major Business
2.2.3 Pfizer Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
2.2.4 Pfizer Chronic Obstructive Pulmonary Disorder (COPD) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Pfizer Recent Developments and Future Plans
2.3 Merck
2.3.1 Merck Details
2.3.2 Merck Major Business
2.3.3 Merck Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
2.3.4 Merck Chronic Obstructive Pulmonary Disorder (COPD) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Merck Recent Developments and Future Plans
2.4 Novartis
2.4.1 Novartis Details
2.4.2 Novartis Major Business
2.4.3 Novartis Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
2.4.4 Novartis Chronic Obstructive Pulmonary Disorder (COPD) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Novartis Recent Developments and Future Plans
2.5 AstraZeneca
2.5.1 AstraZeneca Details
2.5.2 AstraZeneca Major Business
2.5.3 AstraZeneca Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
2.5.4 AstraZeneca Chronic Obstructive Pulmonary Disorder (COPD) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 AstraZeneca Recent Developments and Future Plans
2.6 Boehringer Ingelheim
2.6.1 Boehringer Ingelheim Details
2.6.2 Boehringer Ingelheim Major Business
2.6.3 Boehringer Ingelheim Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
2.6.4 Boehringer Ingelheim Chronic Obstructive Pulmonary Disorder (COPD) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Boehringer Ingelheim Recent Developments and Future Plans
2.7 Teva Pharmaceuticals
2.7.1 Teva Pharmaceuticals Details
2.7.2 Teva Pharmaceuticals Major Business
2.7.3 Teva Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
2.7.4 Teva Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Teva Pharmaceuticals Recent Developments and Future Plans
2.8 Ario Pharma
2.8.1 Ario Pharma Details
2.8.2 Ario Pharma Major Business
2.8.3 Ario Pharma Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
2.8.4 Ario Pharma Chronic Obstructive Pulmonary Disorder (COPD) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Ario Pharma Recent Developments and Future Plans
2.9 Roche
2.9.1 Roche Details
2.9.2 Roche Major Business
2.9.3 Roche Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
2.9.4 Roche Chronic Obstructive Pulmonary Disorder (COPD) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Roche Recent Developments and Future Plans
2.10 Ache
2.10.1 Ache Details
2.10.2 Ache Major Business
2.10.3 Ache Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
2.10.4 Ache Chronic Obstructive Pulmonary Disorder (COPD) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10.5 Ache Recent Developments and Future Plans
2.11 Almirall
2.11.1 Almirall Details
2.11.2 Almirall Major Business
2.11.3 Almirall Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
2.11.4 Almirall Chronic Obstructive Pulmonary Disorder (COPD) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11.5 Almirall Recent Developments and Future Plans
2.12 Aquinox Pharmaceuticals
2.12.1 Aquinox Pharmaceuticals Details
2.12.2 Aquinox Pharmaceuticals Major Business
2.12.3 Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
2.12.4 Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12.5 Aquinox Pharmaceuticals Recent Developments and Future Plans
2.13 Asmacure
2.13.1 Asmacure Details
2.13.2 Asmacure Major Business
2.13.3 Asmacure Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
2.13.4 Asmacure Chronic Obstructive Pulmonary Disorder (COPD) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13.5 Asmacure Recent Developments and Future Plans
2.14 Astellas Pharma
2.14.1 Astellas Pharma Details
2.14.2 Astellas Pharma Major Business
2.14.3 Astellas Pharma Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
2.14.4 Astellas Pharma Chronic Obstructive Pulmonary Disorder (COPD) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.14.5 Astellas Pharma Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Chronic Obstructive Pulmonary Disorder (COPD) Players Market Share in 2021
3.2.2 Top 10 Chronic Obstructive Pulmonary Disorder (COPD) Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Chronic Obstructive Pulmonary Disorder (COPD) Players Head Office, Products and Services Provided
3.4 Chronic Obstructive Pulmonary Disorder (COPD) Mergers & Acquisitions
3.5 Chronic Obstructive Pulmonary Disorder (COPD) New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue and Market Share by Type (2017-2022)
4.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
5.1 Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Application (2017-2022)
5.2 Global Chronic Obstructive Pulmonary Disorder (COPD) Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
6.1 North America Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Type (2017-2028)
6.2 North America Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Application (2017-2028)
6.3 North America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country
6.3.1 North America Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Country (2017-2028)
6.3.2 United States Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Forecast (2017-2028)
6.3.3 Canada Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Forecast (2017-2028)
6.3.4 Mexico Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
7.1 Europe Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Type (2017-2028)
7.2 Europe Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Application (2017-2028)
7.3 Europe Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country
7.3.1 Europe Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Country (2017-2028)
7.3.2 Germany Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Forecast (2017-2028)
7.3.3 France Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Forecast (2017-2028)
7.3.5 Russia Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Forecast (2017-2028)
7.3.6 Italy Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Type (2017-2028)
8.2 Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Application (2017-2028)
8.3 Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Region
8.3.1 Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Region (2017-2028)
8.3.2 China Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Forecast (2017-2028)
8.3.3 Japan Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Forecast (2017-2028)
8.3.4 South Korea Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Forecast (2017-2028)
8.3.5 India Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Forecast (2017-2028)
8.3.7 Australia Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
9.1 South America Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Type (2017-2028)
9.2 South America Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Application (2017-2028)
9.3 South America Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country
9.3.1 South America Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Country (2017-2028)
9.3.2 Brazil Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Forecast (2017-2028)
9.3.3 Argentina Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Type (2017-2028)
10.2 Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Application (2017-2028)
10.3 Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Market Size by Country
10.3.1 Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Country (2017-2028)
10.3.2 Turkey Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Forecast (2017-2028)
10.3.4 UAE Chronic Obstructive Pulmonary Disorder (COPD) Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of Tables
Table 1. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Chronic Obstructive Pulmonary Disorder (COPD) Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue (USD Million) by Region (2017-2022)
Table 5. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Region (2023-2028)
Table 6. GSK Corporate Information, Head Office, and Major Competitors
Table 7. GSK Major Business
Table 8. GSK Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
Table 9. GSK Chronic Obstructive Pulmonary Disorder (COPD) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Pfizer Corporate Information, Head Office, and Major Competitors
Table 11. Pfizer Major Business
Table 12. Pfizer Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
Table 13. Pfizer Chronic Obstructive Pulmonary Disorder (COPD) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Merck Corporate Information, Head Office, and Major Competitors
Table 15. Merck Major Business
Table 16. Merck Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
Table 17. Merck Chronic Obstructive Pulmonary Disorder (COPD) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Novartis Corporate Information, Head Office, and Major Competitors
Table 19. Novartis Major Business
Table 20. Novartis Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
Table 21. Novartis Chronic Obstructive Pulmonary Disorder (COPD) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. AstraZeneca Corporate Information, Head Office, and Major Competitors
Table 23. AstraZeneca Major Business
Table 24. AstraZeneca Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
Table 25. AstraZeneca Chronic Obstructive Pulmonary Disorder (COPD) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Boehringer Ingelheim Corporate Information, Head Office, and Major Competitors
Table 27. Boehringer Ingelheim Major Business
Table 28. Boehringer Ingelheim Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
Table 29. Boehringer Ingelheim Chronic Obstructive Pulmonary Disorder (COPD) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Teva Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 31. Teva Pharmaceuticals Major Business
Table 32. Teva Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
Table 33. Teva Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Ario Pharma Corporate Information, Head Office, and Major Competitors
Table 35. Ario Pharma Major Business
Table 36. Ario Pharma Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
Table 37. Ario Pharma Chronic Obstructive Pulmonary Disorder (COPD) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Roche Corporate Information, Head Office, and Major Competitors
Table 39. Roche Major Business
Table 40. Roche Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
Table 41. Roche Chronic Obstructive Pulmonary Disorder (COPD) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Ache Corporate Information, Head Office, and Major Competitors
Table 43. Ache Major Business
Table 44. Ache Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
Table 45. Ache Chronic Obstructive Pulmonary Disorder (COPD) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 46. Almirall Corporate Information, Head Office, and Major Competitors
Table 47. Almirall Major Business
Table 48. Almirall Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
Table 49. Almirall Chronic Obstructive Pulmonary Disorder (COPD) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 50. Aquinox Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 51. Aquinox Pharmaceuticals Major Business
Table 52. Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
Table 53. Aquinox Pharmaceuticals Chronic Obstructive Pulmonary Disorder (COPD) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 54. Asmacure Corporate Information, Head Office, and Major Competitors
Table 55. Asmacure Major Business
Table 56. Asmacure Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
Table 57. Asmacure Chronic Obstructive Pulmonary Disorder (COPD) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 58. Astellas Pharma Corporate Information, Head Office, and Major Competitors
Table 59. Astellas Pharma Major Business
Table 60. Astellas Pharma Chronic Obstructive Pulmonary Disorder (COPD) Product and Solutions
Table 61. Astellas Pharma Chronic Obstructive Pulmonary Disorder (COPD) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 62. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 63. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 64. Breakdown of Chronic Obstructive Pulmonary Disorder (COPD) by Company Type (Tier 1, Tier 2 and Tier 3)
Table 65. Chronic Obstructive Pulmonary Disorder (COPD) Players Head Office, Products and Services Provided
Table 66. Chronic Obstructive Pulmonary Disorder (COPD) Mergers & Acquisitions in the Past Five Years
Table 67. Chronic Obstructive Pulmonary Disorder (COPD) New Entrants and Expansion Plans
Table 68. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue (USD Million) by Type (2017-2022)
Table 69. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Share by Type (2017-2022)
Table 70. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Forecast by Type (2023-2028)
Table 71. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Application (2017-2022)
Table 72. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Forecast by Application (2023-2028)
Table 73. North America Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Type (2017-2022) & (USD Million)
Table 74. North America Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Type (2023-2028) & (USD Million)
Table 75. North America Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Application (2017-2022) & (USD Million)
Table 76. North America Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Application (2023-2028) & (USD Million)
Table 77. North America Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Country (2017-2022) & (USD Million)
Table 78. North America Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Country (2023-2028) & (USD Million)
Table 79. Europe Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Type (2017-2022) & (USD Million)
Table 80. Europe Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Type (2023-2028) & (USD Million)
Table 81. Europe Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Application (2017-2022) & (USD Million)
Table 82. Europe Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Application (2023-2028) & (USD Million)
Table 83. Europe Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Country (2017-2022) & (USD Million)
Table 84. Europe Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Country (2023-2028) & (USD Million)
Table 85. Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Type (2017-2022) & (USD Million)
Table 86. Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Type (2023-2028) & (USD Million)
Table 87. Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Application (2017-2022) & (USD Million)
Table 88. Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Application (2023-2028) & (USD Million)
Table 89. Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Region (2017-2022) & (USD Million)
Table 90. Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Region (2023-2028) & (USD Million)
Table 91. South America Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Type (2017-2022) & (USD Million)
Table 92. South America Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Type (2023-2028) & (USD Million)
Table 93. South America Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Application (2017-2022) & (USD Million)
Table 94. South America Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Application (2023-2028) & (USD Million)
Table 95. South America Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Country (2017-2022) & (USD Million)
Table 96. South America Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Country (2023-2028) & (USD Million)
Table 97. Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Type (2017-2022) & (USD Million)
Table 98. Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Type (2023-2028) & (USD Million)
Table 99. Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Application (2017-2022) & (USD Million)
Table 100. Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Application (2023-2028) & (USD Million)
Table 101. Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Country (2017-2022) & (USD Million)
Table 102. Middle East & Africa Chronic Obstructive Pulmonary Disorder (COPD) Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. Chronic Obstructive Pulmonary Disorder (COPD) Picture
Figure 2. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Type in 2021
Figure 3. Short-Acting Bronchodilators
Figure 4. Corticosteroids
Figure 5. Methylxanthines
Figure 6. Long-Acting Bronchodilators
Figure 7. Phosphodiesterase-4 Inhibitors
Figure 8. Others
Figure 9. Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Application in 2021
Figure 10. Hospital Picture
Figure 11. Clinic Picture
Figure 12. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 13. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue and Forecast (2017-2028) & (USD Million)
Figure 14. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Region (2017-2028)
Figure 15. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Region in 2021
Figure 16. North America Chronic Obstructive Pulmonary Disorder (COPD) Revenue (USD Million) and Growth Rate (2017-2028)
Figure 17. Europe Chronic Obstructive Pulmonary Disorder (COPD) Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Revenue (USD Million) and Growth Rate (2017-2028)
Figure 19. South America Chronic Obstructive Pulmonary Disorder (COPD) Revenue (USD Million) and Growth Rate (2017-2028)
Figure 20. Middle East and Africa Chronic Obstructive Pulmonary Disorder (COPD) Revenue (USD Million) and Growth Rate (2017-2028)
Figure 21. Chronic Obstructive Pulmonary Disorder (COPD) Market Drivers
Figure 22. Chronic Obstructive Pulmonary Disorder (COPD) Market Restraints
Figure 23. Chronic Obstructive Pulmonary Disorder (COPD) Market Trends
Figure 24. GSK Recent Developments and Future Plans
Figure 25. Pfizer Recent Developments and Future Plans
Figure 26. Merck Recent Developments and Future Plans
Figure 27. Novartis Recent Developments and Future Plans
Figure 28. AstraZeneca Recent Developments and Future Plans
Figure 29. Boehringer Ingelheim Recent Developments and Future Plans
Figure 30. Teva Pharmaceuticals Recent Developments and Future Plans
Figure 31. Ario Pharma Recent Developments and Future Plans
Figure 32. Roche Recent Developments and Future Plans
Figure 33. Ache Recent Developments and Future Plans
Figure 34. Almirall Recent Developments and Future Plans
Figure 35. Aquinox Pharmaceuticals Recent Developments and Future Plans
Figure 36. Asmacure Recent Developments and Future Plans
Figure 37. Astellas Pharma Recent Developments and Future Plans
Figure 38. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Share by Players in 2021
Figure 39. Chronic Obstructive Pulmonary Disorder (COPD) Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 40. Global Top 3 Players Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share in 2021
Figure 41. Global Top 10 Players Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share in 2021
Figure 42. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 43. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Share by Type in 2021
Figure 44. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share Forecast by Type (2023-2028)
Figure 45. Global Chronic Obstructive Pulmonary Disorder (COPD) Revenue Share by Application in 2021
Figure 46. Global Chronic Obstructive Pulmonary Disorder (COPD) Market Share Forecast by Application (2023-2028)
Figure 47. North America Chronic Obstructive Pulmonary Disorder (COPD) Sales Market Share by Type (2017-2028)
Figure 48. North America Chronic Obstructive Pulmonary Disorder (COPD) Sales Market Share by Application (2017-2028)
Figure 49. North America Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Country (2017-2028)
Figure 50. United States Chronic Obstructive Pulmonary Disorder (COPD) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Canada Chronic Obstructive Pulmonary Disorder (COPD) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Mexico Chronic Obstructive Pulmonary Disorder (COPD) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Europe Chronic Obstructive Pulmonary Disorder (COPD) Sales Market Share by Type (2017-2028)
Figure 54. Europe Chronic Obstructive Pulmonary Disorder (COPD) Sales Market Share by Application (2017-2028)
Figure 55. Europe Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Country (2017-2028)
Figure 56. Germany Chronic Obstructive Pulmonary Disorder (COPD) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. France Chronic Obstructive Pulmonary Disorder (COPD) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. United Kingdom Chronic Obstructive Pulmonary Disorder (COPD) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Russia Chronic Obstructive Pulmonary Disorder (COPD) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Italy Chronic Obstructive Pulmonary Disorder (COPD) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Sales Market Share by Type (2017-2028)
Figure 62. Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Sales Market Share by Application (2017-2028)
Figure 63. Asia-Pacific Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Region (2017-2028)
Figure 64. China Chronic Obstructive Pulmonary Disorder (COPD) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. Japan Chronic Obstructive Pulmonary Disorder (COPD) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. South Korea Chronic Obstructive Pulmonary Disorder (COPD) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. India Chronic Obstructive Pulmonary Disorder (COPD) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. Southeast Asia Chronic Obstructive Pulmonary Disorder (COPD) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Australia Chronic Obstructive Pulmonary Disorder (COPD) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. South America Chronic Obstructive Pulmonary Disorder (COPD) Sales Market Share by Type (2017-2028)
Figure 71. South America Chronic Obstructive Pulmonary Disorder (COPD) Sales Market Share by Application (2017-2028)
Figure 72. South America Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Country (2017-2028)
Figure 73. Brazil Chronic Obstructive Pulmonary Disorder (COPD) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Argentina Chronic Obstructive Pulmonary Disorder (COPD) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Middle East and Africa Chronic Obstructive Pulmonary Disorder (COPD) Sales Market Share by Type (2017-2028)
Figure 76. Middle East and Africa Chronic Obstructive Pulmonary Disorder (COPD) Sales Market Share by Application (2017-2028)
Figure 77. Middle East and Africa Chronic Obstructive Pulmonary Disorder (COPD) Revenue Market Share by Country (2017-2028)
Figure 78. Turkey Chronic Obstructive Pulmonary Disorder (COPD) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 79. Saudi Arabia Chronic Obstructive Pulmonary Disorder (COPD) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 80. UAE Chronic Obstructive Pulmonary Disorder (COPD) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 81. Methodology
Figure 82. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
